LGM Pharma
LGM Pharma is a U.S.-based CDMO and API sourcing company serving small and mid-size biopharma, biotechnology, and 503A/503B compounding pharmacy customers with API procurement, drug product manufacturing, and analytical testing services.
- Company typePrivate
- Founded2005
- HeadquartersNashville, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What LGM Pharma does
LGM Pharma is a U.S.-headquartered contract development and manufacturing organization (CDMO) and active pharmaceutical ingredient (API) sourcing company headquartered in Boca Raton, Florida. The business operates three integrated service lines: API sourcing through a network of more than 220 pre-qualified cGMP manufacturers, CDMO drug product services across oral solids (including orally disintegrating tablets), liquids, suspensions, semi-solids, and suppositories, and analytical testing including USP <85> bacterial endotoxin testing and proprietary PCR-based rapid sterility testing. Manufacturing capacity totals more than 100,000 square feet across facilities in Texas, Colorado, California, Florida, and Kentucky, with DEA licensing for Class II-V controlled substances, and the company reports an annual capacity of 35 million suppository doses. Customers include small and mid-size biopharmaceutical firms developing 505(b)(2), NDA, and ANDA products, biotechnology companies, and 503A pharmacies and 503B outsourcing facilities requiring USP-compliant testing.
The business model is project-based B2B services revenue, with multi-year contracts and custom quotation rather than published pricing. LGM monetizes across project-based CDMO contracts (formulation development, clinical and commercial manufacturing), transactional API procurement fees with embedded logistics and regulatory support, and fee-for-service analytical testing for compounders and manufacturers. The company has grown headcount from approximately 33 to over 235 employees over roughly five years and has committed $15 million in cumulative U.S. manufacturing expansion across 2025 and 2026. Under private equity ownership of New Harbor Capital since 2017, LGM additionally acquired Nexgen in 2020 to formalize its CDMO division and has pursued selective co-development activity, including a 2024 partnership with N-Zyme Biomedical on a pepsin inhibitor for reflux disease and a dedicated GLP-1 / obesity drug supply chain service offering. No public revenue figure is disclosed in available sources.
Customers are principally mid-market biopharma and compounding pharmacy organizations lacking in-house manufacturing and analytical capacity, with sales driven by enterprise field engagement and industry-event presence (e.g., DCAT Week) rather than self-serve digital channels. Forward product strategy is centered on U.S. capacity expansion, accelerated analytical turnaround (5-day sterility versus 14-day industry standard), and selective moves into differentiated therapeutic supply chains such as peptide-based metabolic therapies.
LGM Pharma firmographics
Firmographics- Name
- LGM Pharma
- Legal name
- LGM Pharma LLC
- Website
- https://lgmpharma.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- LGM Pharma is a U.S.-based CDMO and API sourcing company serving small and mid-size biopharma, biotechnology, and 503A/503B compounding pharmacy customers with API procurement, drug product manufacturing, and analytical testing services.
- Ownership category
- akta.pro rank
LGM Pharma industry classification
Industry- Product category
- Contract Pharmaceutical Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
Keywords
Where LGM Pharma is headquartered
LocationHeadquarters
- HQ city
- Nashville
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
LGM Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- CDMO Drug Product Services: Contract development and manufacturing organization services including formulation development, drug product manufacturing for oral solids, liquids, suspensions, semi-solids, and suppositories. Revenue generated through project-based contracts and commercial manufacturing agreements.
- API Sourcing and Procurement: Active Pharmaceutical Ingredient sourcing through a global network of over 220 pre-qualified API manufacturers. Services include procurement, logistics, regulatory support, and manufacturer management.
- Analytical Testing Services: Contract analytical testing including USP <85> bacterial endotoxins, sterility testing, method validation/verification, stability studies, and microbiology testing for 503A/503B compounders and pharmaceutical manufacturers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing for CDMO and API sourcing services |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
LGM Pharma product offering
Product offeringCore offering
LGM Pharma is a Contract Development and Manufacturing Organization (CDMO) providing an integrated service platform across the full drug product lifecycle. The company sources Active Pharmaceutical Ingredients (APIs) through a global network of 220+ pre-qualified cGMP manufacturers and provides formulation development, commercial manufacturing across multiple dosage forms (oral solids, liquids, suspensions, semi-solids, suppositories), regulatory management, and analytical testing services from U.S.-based facilities.
Product overview
LGM Pharma is a Contract Development and Manufacturing Organization (CDMO) providing an integrated full drug product lifecycle service platform combining API sourcing and CDMO services. The core offering consists of three main pillars: (1) API Products and API Sourcing services leveraging a global network of over 220 pre-qualified cGMP manufacturers; (2) CDMO Services encompassing formulation development, commercial manufacturing across multiple dosage forms (oral solids, liquids/suspensions, semi-solids, suppositories), and regulatory management; and (3) Analytical Services including analytical testing, stability studies, and specialized testing for compounders. The company operates U.S.-based manufacturing facilities in Texas, Colorado, California, Florida, Kentucky, and provides end-to-end services from API sourcing through drug product commercialization.
Differentiator
Problem solved
Functional benefit
Products and services
- API Sourcing Strategic sourcing of Active Pharmaceutical Ingredients (APIs) from a global network of 220+ pre-qualified cGMP manufacturers, including regulatory support, logistics, and manufacturer management. Targeted at pharmaceutical and biotech companies seeking supply chain resilience for complex and niche APIs.
- API Products Procurement and delivery of niche and complex active pharmaceutical ingredients, with import handling and comprehensive documentation including Certificates of Analysis. Sourced from pre-qualified cGMP manufacturers globally.
- CDMO Services Contract Development and Manufacturing Organization services covering the full drug product lifecycle from concept through commercialization, including formulation development, commercial manufacturing for oral solids, liquids, suspensions, semi-solids, and suppositories, plus regulatory management. Served from 100,000+ square feet of U.S. cGMP facilities including DEA-licensed sites for Class II-V controlled substances.
- Analytical Testing Services Comprehensive analytical method development, validation, and testing for APIs and drug products including USP <85> bacterial endotoxins testing using gel-clot, kinetic turbidimetric, and chromogenic methods, plus method validation/verification, microbiology, and stability studies for pharmaceutical manufacturers.
- Stability Services ICH-compliant stability testing programs including long-term, accelerated, photostability, freeze-thaw, and bench-top stability studies for APIs and drug products using validated analytical methods.
- Analytical Testing Services for Compounders Specialized USP-compliant testing for 503A compounding pharmacies and 503B outsourcing facilities, including USP <71> sterility, USP <85> bacterial endotoxins, USP <61>/<62> microbial limits, and rapid sterility methods to support batch release of compounded preparations.
- Obesity Drug Supply Chain Services Specialized API sourcing and supply chain services for GLP-1 and peptide-based obesity drugs, including supplier qualification and diversification for semaglutide, tirzepatide, and next-generation metabolic therapies.
Quantifiable outcome
- Rapid sterility testing reduces standard 14-day process to 5 days
- +3 more outcomes
Companies that use LGM Pharma
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
LGM Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
LGM Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- N-Zyme BiomedicalminorLGM Pharma and N-Zyme Biomedical are jointly developing the world's first pepsin inhibitor for reflux disease, representing a strategic co-development collaboration in innovative drug delivery technology.
Scale indicators8 records
Recent moves10 records
Expansion highlights5 records
LGM Pharma competitors and assessment
Company assessmentDirect peers
- Hovione: Privately-held, mid-sized integrated CDMO with strong API and drug product capabilities serving small to mid-size pharma globally. Highly comparable to LGM in scope (API + finished dose), customer base, and integrated model.
- Dishman Carbogen Amcis: Integrated API and drug product CDMO serving global pharma customers, including niche and complex APIs. Highly comparable to LGM's API sourcing and CDMO dual-pillar model.
- Piramal Pharma Solutions: Global CDMO offering API, drug product, and analytical services across multiple dosage forms. Comparable integrated offering and target customer base of small/mid biopharma.
- EUROAPI: European-headquartered API and CDMO spun out from Sanofi, serving generic and branded pharma with integrated API and drug substance services. Comparable in API sourcing/distribution roots and finished product development.
- Curia (formerly AMRI): CDMO providing API development, drug product manufacturing, and analytical services globally. Direct overlap with LGM's service portfolio and customer profile.
- Aenova: Mid-market European CDMO offering solid, semi-solid, liquid, and sterile drug product manufacturing plus API services. Closely comparable in service breadth and target customer segment.
- Cambrex: PE-owned (Permira) CDMO specializing in API and finished dose development/manufacturing for generic and innovative pharma. Comparable in business model and small-to-mid customer focus, though at larger scale than LGM.
- PCI Pharma Services: PE-backed global CDMO focused on clinical and commercial drug product manufacturing, packaging, and serialization. Comparable in PE ownership profile, integrated service model, and serialization capabilities.
Broad incumbents
- Catalent: Large global CDMO offering broad formulation, manufacturing, and packaging services across oral, sterile, and biologic dosage forms. Overlaps with LGM in drug product services but at substantially greater scale and broader scope.
- Thermo Fisher Scientific (Patheon Pharma Services): Global CDMO/CMO within Thermo Fisher serving large pharma with API, oral solid dose, sterile, and biopharmaceutical manufacturing. Competes with LGM for larger commercial contracts but at vastly greater scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
LGM Pharma social profiles
Digital presenceLGM Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
LGM Pharma leadership team
Management profileNumber of profiles
Profiles7 records
LGM Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LGM Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LGM Pharma
What does LGM Pharma do?
LGM Pharma is a Contract Development and Manufacturing Organization (CDMO) providing an integrated service platform across the full drug product lifecycle. The company sources Active Pharmaceutical Ingredients (APIs) through a global network of 220+ pre-qualified cGMP manufacturers and provides formulation development, commercial manufacturing across multiple dosage forms (oral solids, liquids, suspensions, semi-solids, suppositories), regulatory management, and analytical testing services from U.S.-based facilities.
Is LGM Pharma a public or private company?
LGM Pharma is a private company. It is classified as private equity controlled and is currently operating.
When was LGM Pharma founded?
LGM Pharma was founded in 2005. It employs 101 to 250 people.
Where is LGM Pharma based?
LGM Pharma is headquartered in Nashville, United States, in the North America region.
How does LGM Pharma make money?
Three revenue lines are on record. CDMO Drug Product Services are the primary driver. The others are API Sourcing and Procurement and analytical Testing Services.
Who are LGM Pharma's main competitors?
Direct peers on record are Hovione, Dishman Carbogen Amcis, Piramal Pharma Solutions, EUROAPI, Curia (formerly AMRI), Aenova, Cambrex and PCI Pharma Services. Broad incumbents are Catalent and Thermo Fisher Scientific (Patheon Pharma Services).
Does LGM Pharma have an API?
No public API is recorded for LGM Pharma.
What industry is LGM Pharma in?
LGM Pharma's product category is Contract Pharmaceutical Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.